spacer
home > epc > winter 2009 > the heart of the matter
PUBLICATIONS
European Pharmaceutical Contractor

The Heart of the Matter

 

Cardiac safety is the primary reason for drug withdrawals and labelling challenges. As a result, industry regulations are under increased scrutiny. Biopharmaceutical, CROs and medical device companies are constantly tasked to provide quality electrocardiogram (ECG) data that are critical to ensuring the most accurate assessment of a new drug’s cardiac effect. ECG data are used to assess the effect of investigational drugs on the electrical functions of the heart. Centralising the process of collection and standardisation of quality ECG data not only reduces inconsistencies that may occur from site to site, but also alleviates laboratory workloads. This article discusses the regulatory requirements in relation to ECGs and highlights the benefits of a centralised versus a decentralised approach.

LEGISLATIVE OVERVIEW

Recent concerns over the cardiac effects of new pharmaceutical products have triggered greater regulatory scrutiny for all new compounds and final drugs prior to reaching the marketplace. While there is no legislative mandate in relation to ECG assessment across all clinical trials, the requirement to conduct a thorough ECG trial (TET) for new compounds has been mandated by the US Food and Drug Administration (FDA) with limited exceptions. This is a result of the introduction of the ICH E14 guideline, which was developed to assess QT/QTc prolongation in new drugs to determine cardiac safety risks.

The ICH E14 guideline recommends that a TET should be performed and if any cardiac safety concerns are raised, Phase III trials will require more robust or intense ECG collection. Unlike many other clinical trials, the TET typically uses a centralised system, which has proven to greatly improve the accuracy and reliability of ECG data in clinical trials. This centralised approach uses standardised digital ECG machines for collection and a centralised high resolution data analysis supplied by a core laboratory.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer

Amy Furlong has been Executive Vice President of Cardiac Safety at ERT since December 2005, and previously served as Senior Vice President of Regulatory Compliance. She holds a Bachelor of Science degree in Biology and a Master of Science degree in Quality Assurance and Regulatory Affairs from Temple University’s School of Pharmacy. Amy has more than 10 years of clinical research experience specialising in regulatory compliance and computer system validation.

spacer
Amy Furlong
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

The Latest Innovations in HPAPI Manufacturing Technologies

SMi’s inaugural Highly Potent Active Pharmaceutical Ingredients USA Conference, will focus on the latest innovative manufacturing technologies with a special spotlight presentation on effective and safe containment solutions for biologics based HPAPIs, along with cleaning and cross contamination requirements.
More info >>

White Papers

Wrap Around Label - A Lot of Content in a Small Space

Faubel & Co. Nachfolger GmbH

One of the world’s largest contract research organizations for the planning and conducting of clinical trials was faced with the challenge of accommodating many different national languages on an inhaler. The inhaler was then to be distributed in 47 countries. Due to the impressive quality and reliable collaboration, the organization commissioned Faubel with finding the optimal labeling solution for the inhaler.
More info >>

 
Industry Events

CPhI & P-MEC India

26-28 November 2019, India Expo Centre, Greater Noida, Delhi NCR, India

As the pharma industry looks increasingly towards India for high quality, low cost pharma solutions, CPhI & P-MEC India is the ideal event for companies wanting to pick up on the latest trends and innovations the market has to offer. At CPhI & P-MEC India, you will meet the movers and shakers from India's pharma machinery, technology and ingredients industries, giving you a competitive advantage that will help grow your business.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement